Aardvark Therapeutics (AARD) Competitors $10.55 -0.57 (-5.13%) As of 02:46 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock AARD vs. LENZ, SNDX, CVAC, NUVB, PRAX, XERS, QURE, NRIX, RCKT, and AVXLShould you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include LENZ Therapeutics (LENZ), Syndax Pharmaceuticals (SNDX), CureVac (CVAC), Nuvation Bio (NUVB), Praxis Precision Medicines (PRAX), Xeris Biopharma (XERS), uniQure (QURE), Nurix Therapeutics (NRIX), Rocket Pharmaceuticals (RCKT), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry. Aardvark Therapeutics vs. LENZ Therapeutics Syndax Pharmaceuticals CureVac Nuvation Bio Praxis Precision Medicines Xeris Biopharma uniQure Nurix Therapeutics Rocket Pharmaceuticals Anavex Life Sciences LENZ Therapeutics (NASDAQ:LENZ) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability. Do insiders and institutionals believe in LENZ or AARD? 54.3% of LENZ Therapeutics shares are owned by institutional investors. 38.4% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is LENZ or AARD more profitable? Aardvark Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -58.48% -55.50% Aardvark Therapeutics N/A N/A N/A Does the media refer more to LENZ or AARD? In the previous week, Aardvark Therapeutics had 8 more articles in the media than LENZ Therapeutics. MarketBeat recorded 11 mentions for Aardvark Therapeutics and 3 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.99 beat Aardvark Therapeutics' score of 0.09 indicating that LENZ Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, LENZ or AARD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$124.65M-$1.77-16.06Aardvark TherapeuticsN/AN/AN/AN/AN/A Does the MarketBeat Community favor LENZ or AARD? LENZ Therapeutics received 7 more outperform votes than Aardvark Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave LENZ Therapeutics an outperform vote while only 88.89% of users gave Aardvark Therapeutics an outperform vote. CompanyUnderperformOutperformLENZ TherapeuticsOutperform Votes15100.00% Underperform VotesNo VotesAardvark TherapeuticsOutperform Votes888.89% Underperform Votes111.11% Do analysts rate LENZ or AARD? LENZ Therapeutics presently has a consensus target price of $46.60, suggesting a potential upside of 63.97%. Aardvark Therapeutics has a consensus target price of $31.25, suggesting a potential upside of 182.29%. Given Aardvark Therapeutics' higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryLENZ Therapeutics beats Aardvark Therapeutics on 8 of the 12 factors compared between the two stocks. Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AARD vs. The Competition Export to ExcelMetricAardvark TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$240.18M$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E RatioN/A9.0426.7819.69Price / SalesN/A253.23386.97118.34Price / CashN/A65.8538.2534.62Price / BookN/A6.406.744.50Net IncomeN/A$143.98M$3.23B$248.32M7 Day Performance21.78%1.90%1.49%-0.03%1 Month Performance44.52%4.01%11.47%12.72%1 Year PerformanceN/A-3.00%16.57%7.38% Aardvark Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AARDAardvark TherapeuticsN/A$10.55-5.1%$31.25+196.2%N/A$228.89MN/A0.0018Analyst DowngradeAnalyst RevisionGap UpLENZLENZ Therapeutics1.8506 of 5 stars$27.34-1.0%$46.60+70.4%+51.1%$777.67MN/A-15.45110Gap UpSNDXSyndax Pharmaceuticals3.825 of 5 stars$8.95-3.6%$35.91+301.2%-48.5%$770.12M$43.72M-2.47110Positive NewsHigh Trading VolumeCVACCureVac3.7084 of 5 stars$3.42+1.5%$14.00+309.4%+18.5%$767.24M$535.18M6.22880News CoverageEarnings ReportNUVBNuvation Bio3.7209 of 5 stars$2.24+3.2%$7.83+249.7%-40.1%$758.64M$10.96M-1.0360News CoveragePRAXPraxis Precision Medicines3.1716 of 5 stars$37.20+0.3%$116.50+213.2%-15.8%$757.73M$8.12M-3.61110Positive NewsXERSXeris Biopharma4.4964 of 5 stars$4.79+3.2%$6.25+30.5%+146.0%$749.08M$203.07M-10.64290Positive NewsAnalyst DowngradeQUREuniQure2.9663 of 5 stars$13.25+4.7%$37.82+185.4%+222.9%$725.78M$27.12M-2.67500Analyst UpgradeOptions VolumeAnalyst RevisionNRIXNurix Therapeutics2.4174 of 5 stars$9.46-1.3%$30.44+221.8%-38.6%$721.19M$56.42M-3.27300Positive NewsAnalyst DowngradeGap UpRCKTRocket Pharmaceuticals4.9055 of 5 stars$6.72+11.1%$40.82+507.4%-70.5%$717.60MN/A-2.44240High Trading VolumeAVXLAnavex Life Sciences3.7387 of 5 stars$8.37+2.4%$44.00+425.7%+78.9%$714.56MN/A-15.2240 Related Companies and Tools Related Companies LENZ Alternatives SNDX Alternatives CVAC Alternatives NUVB Alternatives PRAX Alternatives XERS Alternatives QURE Alternatives NRIX Alternatives RCKT Alternatives AVXL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AARD) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AARD Stock Free AARD Stock Alerts